Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2023/5891532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546774851518464 |
|---|---|
| author | Zijun Ma Kaiqin Jin Mengmeng Yue Xin Chen Jun Chen |
| author_facet | Zijun Ma Kaiqin Jin Mengmeng Yue Xin Chen Jun Chen |
| author_sort | Zijun Ma |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual GIP/GLP-1R agonist approved for the treatment of diabetes mellitus in the United States as a new hypoglycemic medicine. Its hypoglycaemic and weight loss effects have been demonstrated in several large clinical trials, and there is also evidence that it has great potential for cardiovascular protection. In addition, the very concept of synthetic peptides opens up many unknown possibilities for tirzepatide. Ongoing trials (NCT04166773) and evidence suggest that it appears to be a promising drug in the areas of NAFLD, renal, and neuroprotection. Based on preclinical studies and clinical trials, the aim of this article is to discuss the latest clinical developments in tirzepatide, to focus on its differences with other incretin therapies, and to suggest future possibilities and mechanisms of tirzepatide therapy. |
| format | Article |
| id | doaj-art-ebf346f2c12c4f8c8785124c0ae0cc3d |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-ebf346f2c12c4f8c8785124c0ae0cc3d2025-02-03T06:47:16ZengWileyJournal of Diabetes Research2314-67532023-01-01202310.1155/2023/5891532Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 DiabetesZijun Ma0Kaiqin Jin1Mengmeng Yue2Xin Chen3Jun Chen4Sinopharm Dongfeng General HospitalDepartment of CardiologySinopharm Dongfeng General HospitalSinopharm Dongfeng General HospitalSinopharm Dongfeng General HospitalType 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual GIP/GLP-1R agonist approved for the treatment of diabetes mellitus in the United States as a new hypoglycemic medicine. Its hypoglycaemic and weight loss effects have been demonstrated in several large clinical trials, and there is also evidence that it has great potential for cardiovascular protection. In addition, the very concept of synthetic peptides opens up many unknown possibilities for tirzepatide. Ongoing trials (NCT04166773) and evidence suggest that it appears to be a promising drug in the areas of NAFLD, renal, and neuroprotection. Based on preclinical studies and clinical trials, the aim of this article is to discuss the latest clinical developments in tirzepatide, to focus on its differences with other incretin therapies, and to suggest future possibilities and mechanisms of tirzepatide therapy.http://dx.doi.org/10.1155/2023/5891532 |
| spellingShingle | Zijun Ma Kaiqin Jin Mengmeng Yue Xin Chen Jun Chen Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes Journal of Diabetes Research |
| title | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes |
| title_full | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes |
| title_fullStr | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes |
| title_full_unstemmed | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes |
| title_short | Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes |
| title_sort | research progress on the gip glp 1 receptor coagonist tirzepatide a rising star in type 2 diabetes |
| url | http://dx.doi.org/10.1155/2023/5891532 |
| work_keys_str_mv | AT zijunma researchprogressonthegipglp1receptorcoagonisttirzepatidearisingstarintype2diabetes AT kaiqinjin researchprogressonthegipglp1receptorcoagonisttirzepatidearisingstarintype2diabetes AT mengmengyue researchprogressonthegipglp1receptorcoagonisttirzepatidearisingstarintype2diabetes AT xinchen researchprogressonthegipglp1receptorcoagonisttirzepatidearisingstarintype2diabetes AT junchen researchprogressonthegipglp1receptorcoagonisttirzepatidearisingstarintype2diabetes |